A Clinical study of infective Hepatitis treated with Liv.52

Ila V. Desai, M.V. Dudhia and V.K. Gandhi Sheth K.M. School of Post-graduate Medicine and Research and Sheth V.S. General Hospital and Smt. N.H.L. Municipal Medical College, Ahmedabad, India.

Jaundice was observed in all the cases.

The liver was palpable in all the cases except one patient; and it was tender in 83.85% of them. The consistency was soft in all cases.

Splenic enlargement was present in 8 cases.

Clinical recovery was judged by duration of symptoms (Table II). In almost all cases of the trial group the average duration of jaundice, after starting the treatment was 10 days and in the control group it was 15 days. Fever and anorexia persisted upto 1 week in the trial group while in the control group they persisted upto two weeks.

Table II: Showing clinical recovery — symptom-wise
Symptom		1 Week								2 Weeks								More than 2 Weeks
Liv.52 Cases			%		Control Cases		%		Liv.52 Cases		%		Control Cases		%		Liv.52 Cases		%		Control Cases		%
Fever		10/52		19.23		24/56		42.86		50/52		96.15		35/56		62.5		52/52		100		56/56		100
Anorexia		25/34		73.53		33/46		71.74		32/34		94.12		35/46		76.10		34/34		100		38/46		82.61
Nausea/		20/23		86.96		10/34		29.41		22/23		95.65		29/34		85.30		23/23		100		33/34		97.06
Vomiting						11/34		32.35						27/34		79.41
Jaundice		44/70		62.86		32/56		57.14		57/70		81.43		33/56		58.93		64/70		91.43		41/56		73.21
In the Control Group 4 patients expired, two on the day of admission and two patients two days after admission

Table III: Liver function tests before treatment
Tests								Trial group					Control group
Cases						%			Cases						%
Serum bilirubin (in mg%)					upto 5			51			72.85		32	53.33
5 - 10				15			21.43			20		33.33
more than 10				4			5.72			8		13.33
S.G.P.T. (I.U.)					0 - 45			7			10.00		—	—
46 - 100				28			40.00			10		16.66
101 - 200				21			30.00			16		26.66
more than 200				14			20.00			34		56.66
Thymol turbidity (Units)					0 - 8			13			18.58		41	68.33
8 - 12				51			72.85			14		23.33
more than 12				6			8.57			5		8.33
S. Alkaline phosphatase (K.A.U.)					upto 15			42			60.00		—	—
15 - 60				24			34.28			43		71.66
more than 60				4			5.72			17		28.33
Urine: Bile salts & pigments					Present			62			88.57		57	95.00
Absent				8			11.43			3		5.00

Nausea and vomiting subsided within 5 days in the majority of patients in the trial group and within two weeks in the control group.

In almost all patients in the trial group, the liver receded within 2 to 4 weeks whereas in the control group it receded within 2 to 8 weeks.

The average weight gain was 0.6 kg in two weeks in the trial group.

As compared in Table IV, serum bilirubin returned to normal level in 85.72% of the patients in the Liv.52 group, while in the control group in 57.15% of the patients. This showed that serum bilirubin remained high in the patients of the control group even after two weeks of treatment. At the end of two weeks, 26.78% of the control group continued to have high level of thymol turbidity, whereas in the trial group only 12.85% had high levels. In the trial group 22.85% and in the control group 30.35% showed abnormal level of S.G.P.T.

Table IV: Liver function tests two weeks after treatment
Tests								Trial group					Control group
Cases						%			Cases						%
Serum bilirubin					Normal value			60			85.72		32	57.15
Raised value				10			14.28			24		42.85
S.G.P.T.					Normal value			54			77.15		39	69.65
Raised value				16			22.85			17		30.35
Thymol					Normal value			61			87.15		41	73.22
Railed value				9			12.85			15		26.78
S. Alkaline phosphatase					Normal value			61			87.15		—	—
Raised value				9			12.85			—		—
Urine: Bile salts & pigments					Absent			70			100.00		56	100.00
Present				—			—			—		—

DISCUSSION

When the above two series are compared, it is seen that clinical improvement was more rapid and symptoms subsided earlier in the patients treated with Liv.52.

Tenderness and size of the liver seemed to persist longer in the control than in the trial group.

Liver function tests have shown that Liv.52 brings down the level of serum bilirubin much earlier than in patients treated without Liv.52.

Ramalingam V., Sundaravalli N. (1971); Gupta (1972); Kulkarni (1971) and Mazumdar (1974), in their clinical studies noticed that Liv.52 has been effective in the treatment of infective hepatitis by decreasing its morbidity and the duration of jaundice as well as improving appetite and weight gain.

Patel (1963) and Joglekar (1970) showed its effects on liver cell regeneration and protection against hepatotoxicity.

No untoward side effects of Liv.52 therapy were seen during the trial.

Refference: http://www.himalayahealthcare.com/pdf_files/liv233.pdf